Clinical trials: Angiosarcoma Metastatic
Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma. This study is for patients who have angiosarcoma that has gotten worse after they received chemotherapy.
- Conditions
- Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT02048722
- Testing
- regorafenib
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
This phase II trial studies how well depsipeptide (romidepsin) works in treating patients with metastatic or unresectable soft tissue sarcoma.
- Conditions
- Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma
- Trial name
- NCT00112463
- Testing
- romidepsin
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Angiosarcomas, Soft Tissue Sarcoma
Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
This is an open-label, single-arm, multi-center, Phase 2 study with Paclitaxel in combination with Bevacizumab in patients with Unresectable or Metastatic Angiosarcoma.
- Trial name
- NCT01055028
- Testing
- Bevacizumab, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Stanford University
Sarcoma, Soft Tissue, Soft Tissue Sarcoma
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
The purpose of this research study is to look at whether giving a drug called dexrazoxane with standard of care doxorubicin affects the progression of the disease.
- Conditions
- Sarcoma, Soft Tissue, Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma
- Trial name
- NCT02584309
- Testing
- Dexrazoxane, Doxorubicin
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Washington University School of Medicine
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Sarcoma, Epithelioid Sarcoma
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
The purpose of this study is to determine how well the combination of therapy of talimogene laherparepvec (T-VEC) and pembrolizumab works in the treatment of patients with sarcoma.
- Conditions
- Sarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma
- Trial name
- NCT03069378
- Testing
- Talimogene Laherparepvec (T-VEC), Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
This phase III trial is studying observation to see how well a risk based treatment strategy works in patients with soft tissue sarcoma.
- Conditions
- Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma
- Trial name
- NCT00346164
- Testing
- doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery
- Where
- 187 sites in United States, Australia and 3 more
- Volunteers
- 588 people
- Sponsor
- Children's Oncology Group
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00474994
- Testing
- sunitinib malate
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Angiosarcoma, Metastatic Angiosarcoma
Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
This phase II trial evaluates the effect of sintilimab in treating patients with angiosarcoma that has spread to nearby tissue or lymph nodes (locally advanced), has spread to other places in the body (metastatic), or has come…
- Conditions
- Locally Advanced Angiosarcoma, Metastatic Angiosarcoma, Recurrent Angiosarcoma
- Trial name
- NCT05026736
- Testing
- Quality-of-Life Assessment, Sintilimab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Angiosarcoma, Adult Epithelioid Sarcoma
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
This phase II trial is studying how well sorafenib works in treating patients with metastatic, locally advanced, or recurrent sarcoma.
- Conditions
- Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Leiomyosarcoma, Adult Malignant Fibrous Histiocytoma
- Trial name
- NCT00245102
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- National Cancer Institute (NCI)
Advanced and/or Metastatic Sarcoma
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
The goal of this clinical research study is to learn if the combination of durvalumab and tremelimumab can help to control sarcoma. The safety of this drug combination will also be studied. This is an investigational study.
- Trial name
- NCT02815995
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- M.D. Anderson Cancer Center
Leiomyosarcoma
A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma
The purpose of this study is to learn about the safety and effects of the study medicine (called Ontorpacept or TTI-621) when given alone and when given in combination with doxorubicin for people with leiomyosarcoma.
- Trial name
- TTI-621-03 (NCT04996004)
- Testing
- Ontorpacept (TTI-621), Doxorubicin
- Where
- 23 sites in United States
- Volunteers
- 76 people
- Sponsor
- Pfizer
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating…
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma
- Trial name
- NCT01154452
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)